Current Treatments and Therapeutic Options for COVID-19 Patients: A
Systematic Review

Esmaeil      Mehraeen; Zeinab      Najafi; Bagher      Hayati; Mohammad      Javaherian; Sajad      Rahimi; Omid      Dadras; SeyedAhmad      SeyedAlinaghi; Maryam      Ghadimi; Jean-Marc      Sabatier

Abstract

Introduction: COVID-19 is the third rising epidemic in the 21st century that quickly turned into a worldwide pandemic. Many clinical studies have been achieved to investigate treatments to confront COVID-19. Therefore, we conducted a systematic review to describe the recent treatment strategies to treat COVID-19 patients.

Methods: A systematic search was performed in the databases of PubMed, Scopus, Embase, Science direct, Up to date, and Web of Science using the keywords of Coronavirus, COVID-19, SARS-CoV-2, Novel Coronavirus, 2019-nCoV, Treatment, Medicine, Therapy, Intervention, Drug, Medications, and Cure. All the relevant articles were collected from December 2019 to July 2020.

Results: We included 58 studies including 38 articles (eleven reviews, ten editorial documents, three case reports, one mix method, one cohort study), and 19 published clinical trials. Review of studies showed that Lopinavir/Ritonavir (n=16), Remdesivir (n=13), Convalescent plasma (n=11), Chloroquine (n=11), Ribavirin (n=9), Hydroxychloroquine sulfate (n=8), Traditional Chinese Medicine (TCM) (n=8), and Arbidol (n=7), were the most frequently therapies used to treat COVID-19 patients.

Conclusion: In the absence of definitive treatment protocols, recently proposed approaches have appeared to be an effective therapy for accelerating the recovery of COVID-19 patients. Some of these treatments may have been in the early stages of testing. However, future preclinical and clinical trials are warranted to validate findings.

Keywords: Coronavirus, COVID-19, treatment, medicine, intervention, antiviral, COVID-19 therapy.

Graphical Abstract

[1] 
Ghiasvand F. SeyedAlinaghi S, Tirgar S, Salehi MR, Moradmand-Badie B., Salehi MR, Moradmand-Badie B. A patient with covid-19 pneumonia presenting with plural effusion: A case report. Trop Med Infect Dis  2021; 21(6) ,e170721187994
[PMID:  33200715] 
[2] 
Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese center for disease control and prevention. JAMA  2020; 323(13): 1239-42.
[http://dx.doi.org/10.1001/jama.2020.2648] [PMID:  32091533] 
[3] 
Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med  2020; 382(8): 727-33.
[http://dx.doi.org/10.1056/NEJMoa2001017] [PMID:  31978945] 
[4] 
Mehraeen E, Behnezhad F, Salehi MA, Noori T, Harandi H. SeyedAlinaghi S. Olfactory and gustatory dysfunctions due to the coronavirus disease (COVID-19): a review of current evidence. Eur Arch Otorhinolaryngol  2021; 278(2): 307-12.
[http://dx.doi.org/10.1007/s00405-020-06120-6] [PMID:  32556781] 
[5] 
Mehraeen E, Hayati B, Saeidi S, Heydari M, Seyed Alinaghi S. Selfcare
	instructions for people not requiring hospitalization for coronavirus
	disease 2019 (covid-19). Arch Clin Infect Dis 2020; 15(COVID-
	19): e102978. 
[6] 
Asadollahi Amin AGF, Rezaei H. SeyedAlinaghi S. Asymptomatic SARS-CoV-2ý infection with lung involvement accidentally found on chest CT scan: A case report. Trop Med Infect Dis  2020; 5(2): 56.
[http://dx.doi.org/10.3390/tropicalmed5020056] [PMID:  32272630] 
[7] 
Chang D, Lin M, Wei L, et al. Epidemiologic and clinical characteristics of novel coronavirus infections involving 13 patients outside Wuhan, China. JAMA  2020; 323(11): 1092-3.
[http://dx.doi.org/10.1001/jama.2020.1623] [PMID:  32031568] 
[8] 
Chen J. Pathogenicity and transmissibility of 2019-nCoV-A quick overview and comparison with other emerging viruses. Microbes Infect  2020; 22(2): 69-71.
[http://dx.doi.org/10.1016/j.micinf.2020.01.004] [PMID:  32032682] 
[9] 
Carlos WG, Dela Cruz CS, Cao B, Pasnick S, Jamil S. Novel Wuhan (2019-nCoV) coronavirus. Am J Respir Crit Care Med  2020; 201(4): 7-P8.
[http://dx.doi.org/10.1164/rccm.2014P7] [PMID:  32004066] 
[10] 
Zhang Q, Wang Y, Qi C, Shen L, Li J. Clinical trial analysis of 2019-nCoV therapy registered in China. J Med Virol  2020; 92(6): 540-5.
[http://dx.doi.org/10.1002/jmv.25733] [PMID:  32108352] 
[11] 
Cortegiani A, Ingoglia G, Ippolito M, Giarratano A, Einav S. A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19. J Crit Care  2020; 57: 279-83.
[http://dx.doi.org/10.1016/j.jcrc.2020.03.005] [PMID:  32173110] 
[12] 
McIntosh K, Hirsch MS, Bloom A. Coronavirus disease 2019. Available from:. www.uptodate.com
[13] 
Ahn JY, Sohn Y, Lee SH, et al. Use of convalescent plasma therapy in two COVID-19 patients with acute respiratory distress syndrome in Korea. J Korean Med Sci  2020; 35(14) ,e149
[http://dx.doi.org/10.3346/jkms.2020.35.e149] [PMID:  32281317] 
[14] 
Amirian ES, Levy JK. Current knowledge about the antivirals remdesivir (GS-5734) and GS-441524 as therapeutic options for coronaviruses. One Health  2020; 9 ,100128
[http://dx.doi.org/10.1016/j.onehlt.2020.100128] [PMID:  32258351] 
[15] 
Cai Q, Yang M, Liu D, et al. Experimental treatment with favipiravir for COVID-19: An open-label control study. Engineering (Beijing)  2020; 6(10): 1192-8.
[http://dx.doi.org/10.1016/j.eng.2020.03.007] [PMID:  32346491] 
[16] 
Cao B, Wang Y, Wen D, et al. A trial of lopinavir–ritonavir in adults hospitalized with severe Covid-19. N Engl J Med  2020; 382(19): 1787-99.
[http://dx.doi.org/10.1056/NEJMoa2001282] [PMID:  32187464] 
[17] 
Cao W, Liu X, Bai T, Fan H, Hong K, Song H, Eds. High-dose intravenous
	immunoglobulin as a therapeutic option for deteriorating patients
	with coronavirus disease 2019. Open Forum Infect Dis 2019;
	7(3): ofaa102. 
[http://dx.doi.org/10.1093/ofid/ofaa102] 
[18] 
Chakraborty C, Sharma AR, Sharma G, Bhattacharya M, Lee SS. SARS-CoV-2 causing pneumonia-associated respiratory disorder (COVID-19): diagnostic and proposed therapeutic options. Eur Rev Med Pharmacol Sci  2020; 24(7): 4016-26.
[PMID:  32329877] 
[19] 
Chen C, Huang J, Cheng Z, et al. Favipiravir versus arbidol for covid-
	19: A randomized clinical trial. medRxiv 2020; 20037432. 
[http://dx.doi.org/10.1101/2020.03.17.20037432] 
[20] 
Colson P, Rolain JM, Lagier JC, Brouqui P, Raoult D. Chloroquine and hydroxychloroquine as available weapons to fight COVID-19. Int J Antimicrob Agents  2020; 55(4) ,105932
[http://dx.doi.org/10.1016/j.ijantimicag.2020.105932] [PMID:  32145363] 
[21] 
Chen L, Xiong J, Bao L, Shi Y. Convalescent plasma as a potential therapy for COVID-19. Lancet Infect Dis  2020; 20(4): 398-400.
[http://dx.doi.org/10.1016/S1473-3099(20)30141-9] [PMID:  32113510] 
[22] 
Chang R, Sun W-Z. Repositioning chloroquine as ideal antiviral prophylactic against covid-19-time is now. Drug Discov Today 2020. ,2020030279
[23] 
Chen C, Qi F, Shi K, Li Y, Li J, Chen Y, et al. Thalidomide combined with low-dose glucocorticoid in the treatment of covid-19 pneumonia. Int J Infect Dis  2021; 103: 507-13.
[http://dx.doi.org/10.1016/j.ijid.2020.12.023] 
[24] 
Cunningham AC, Goh HP, Koh D. Treatment of COVID-19: old tricks for new challenges. Crit Care  2020; 24(1): 91.
[http://dx.doi.org/10.1186/s13054-020-2818-6] [PMID:  32178711] 
[25] 
Dong L, Hu S, Gao J. Discovering drugs to treat coronavirus disease 2019 (COVID-19). Drug Discov Ther  2020; 14(1): 58-60.
[http://dx.doi.org/10.5582/ddt.2020.01012] [PMID:  32147628] 
[26] 
Day M. Covid-19: ibuprofen should not be used for managing symptoms, say doctors and scientists.  British Medical Journal Publishing Group 2020; p. 368.
[27] 
Favalli EG, Ingegnoli F, De Lucia O, Cincinelli G, Cimaz R, Caporali R. COVID-19 infection and rheumatoid arthritis: Faraway, so close! Autoimmun Rev  2020; 19(5) ,102523
[http://dx.doi.org/10.1016/j.autrev.2020.102523] [PMID:  32205186] 
[28] 
Gao J, Tian Z, Yang X. Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends  2020; 14(1): 72-3.
[http://dx.doi.org/10.5582/bst.2020.01047] [PMID:  32074550] 
[29] 
Gasmi A, Noor S, Tippairote T, Dadar M, Menzel A, Bjørklund G. Individual risk management strategy and potential therapeutic options for the COVID-19 pandemic. Clin Immunol  2020; 215 ,108409
[http://dx.doi.org/10.1016/j.clim.2020.108409] [PMID:  32276137] 
[30] 
Gautret P, Lagier J-C, Parola P, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents  2020; 56(1) ,105949
[http://dx.doi.org/10.1016/j.ijantimicag.2020.105949] [PMID:  32205204] 
[31] 
Guo Y-R, Cao Q-D, Hong Z-S, et al. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak–an update on the status. Mil Med Res  2020; 7(1): 1-10.
[http://dx.doi.org/10.1186/s40779-020-00240-0] [PMID:  31928528] 
[32] 
Holshue ML, DeBolt C, Lindquist S, et al. First case of 2019 novel coronavirus in the United States. N Engl J Med  2020; 382(10): 929-36.
[http://dx.doi.org/10.1056/NEJMoa2001191] [PMID:  32004427] 
[33] 
Hung IF, Lung KC, Tso EY, et al. Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial. Lancet  2020; 395(10238): 1695-704.
[http://dx.doi.org/10.1016/S0140-6736(20)31042-4] [PMID:  32401715] 
[34] 
Izzedine H, Jhaveri KD, Perazella MA. COVID-19 therapeutic options for patients with kidney disease. Kidney Int  2020; 97(6): 1297-8.
[http://dx.doi.org/10.1016/j.kint.2020.03.015] [PMID:  32317113] 
[35] 
Li Y, Xie Z, Lin W, et al. An exploratory randomized, controlled
	study on the efficacy and safety of lopinavir/ritonavir or arbidol treating
	adult patients hospitalized with mild/moderate COVID-19
	(ELACOI). medRxiv 2020; 20038984. 
[http://dx.doi.org/10.1101/2020.03.19.20038984] 
[36] 
Li G, De Clercq E. Therapeutic options for the 2019 novel coronavirus (2019-nCoV). Nat Rev Drug Discov  2020; 19(3): 149-50.
[http://dx.doi.org/10.1038/d41573-020-00016-0] [PMID:  32127666] 
[37] 
Lim J, Jeon S, Shin H-Y, et al. Case of the index patient who caused tertiary transmission of COVID-19 infection in Korea: the application of lopinavir/ritonavir for the treatment of COVID-19 infected pneumonia monitored by quantitative RT-PCR. J Korean Med Sci  2020; 35(6) ,e79
[http://dx.doi.org/10.3346/jkms.2020.35.e79] [PMID:  32056407] 
[38] 
Luo H, Tang QL, Shang YX, et al. Can Chinese medicine be used for prevention of corona virus disease 2019 (COVID-19)? A review of historical classics, research evidence and current prevention programs. Chin J Integr Med  2020; 26(4): 243-50.
[http://dx.doi.org/10.1007/s11655-020-3192-6] [PMID:  32065348] 
[39] 
Luo P, Liu Y, Qiu L, Liu X, Liu D, Li J. Tocilizumab treatment in COVID-19: A single center experience. J Med Virol  2020; 92(7): 814-8.
[http://dx.doi.org/10.1002/jmv.25801] [PMID:  32253759] 
[40] 
Lu H. Drug treatment options for the 2019-new coronavirus (2019-nCoV). Biosci Trends  2020; 14(1): 69-71.
[http://dx.doi.org/10.5582/bst.2020.01020] [PMID:  31996494] 
[41] 
Ma J, Xia P, Zhou Y, et al. Potential effect of blood purification therapy in reducing cytokine storm as a late complication of critically ill COVID-19. Clin Immunol  2020; 214 ,108408
[http://dx.doi.org/10.1016/j.clim.2020.108408] [PMID:  32247038] 
[42] 
Rajendran K, Krishnasamy N, Rangarajan J, Rathinam J, Natarajan M, Ramachandran A. Convalescent plasma transfusion for the treatment of COVID-19: Systematic review. J Med Virol  2020; 92(9): 1475-83.
[http://dx.doi.org/10.1002/jmv.25961] [PMID:  32356910] 
[43] 
Ren JHZA, Jun Wang Xi. Traditional Chinese medicine for COVID-19 treatment. Pharmacol Res  2020; 155 ,104768
[http://dx.doi.org/10.1016/j.phrs.2020.104768] [PMID:  32222346] 
[44] 
Rosa SGV, Santos WC. Clinical trials on drug repositioning for
	COVID-19 treatment. Rev Panam Salud Publica 2020; e40: 44 
[45] 
Roback JD, Guarner J. Convalescent plasma to treat COVID-19: possibilities and challenges. JAMA  2020; 323(16): 1561-2.
[http://dx.doi.org/10.1001/jama.2020.4940] [PMID:  32219429] 
[46] 
Sanders JM, Monogue ML, Jodlowski TZ, Cutrell JB. Pharmacologic treatments for coronavirus disease 2019 (COVID-19): A review. JAMA  2020; 323(18): 1824-36.
[PMID:  32282022] 
[47] 
Sarma P, Prajapat M, Avti P, Kaur H, Kumar S, Medhi B. Therapeutic options for the treatment of 2019-novel coronavirus: An evidence-based approach. Indian J Pharmacol  2020; 52(1): 1-5.
[http://dx.doi.org/10.4103/ijp.IJP_119_20] [PMID:  32201439] 
[48] 
Sarma P, Kaur H, Kumar H, et al. Virological and clinical cure in COVID-19 patients treated with hydroxychloroquine: A systematic review and meta-analysis. J Med Virol  2020; 92(7): 776-85.
[http://dx.doi.org/10.1002/jmv.25898] [PMID:  32297988] 
[49] 
Sheahan TP, Sims AC, Leist SR, et al. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat Commun  2020; 11(1): 222.
[http://dx.doi.org/10.1038/s41467-019-13940-6] [PMID:  31924756] 
[50] 
Stebbing J, Phelan A, Griffin I, et al. COVID-19: combining antiviral and anti-inflammatory treatments. Lancet Infect Dis  2020; 20(4): 400-2.
[http://dx.doi.org/10.1016/S1473-3099(20)30132-8] [PMID:  32113509] 
[51] 
Sun ML, Yang JM, Sun YP, Su GH. Inhibitors of RAS might be a
	good choice for the therapy of COVID-19 pneumonia. Zhonghua jie
	he he hu xi za 2020; 43(0): E014. 
[PMID:  32061198] 
[52] 
Shen C, Wang Z, Zhao F, et al. Treatment of 5 critically ill patients withcovid-19 with convalescent plasma. JAMA  2020; 323(16): 1582-9.
[http://dx.doi.org/10.1001/jama.2020.4783] [PMID:  32219428] 
[53] 
Syal K. COVID-19: Herd immunity and convalescent plasma transfer therapy. J Med Virol  2020; 92(9): 1380-2.
[http://dx.doi.org/10.1002/jmv.25870] [PMID:  32281679] 
[54] 
Tiberghien P, de Lamballerie X, Morel P, Gallian P, Lacombe K, Yazdanpanah Y. Collecting and evaluating convalescent plasma for COVID-19 treatment: why and how? Vox Sang  2020; 115(6): 488-94.
[http://dx.doi.org/10.1111/vox.12926] [PMID:  32240545] 
[55] 
Tanne JH. Covid-19: FDA approves use of convalescent plasma to treat critically ill patients. BMJ  2020; 368: m1256.
[http://dx.doi.org/10.1136/bmj.m1256] [PMID:  32217555] 
[56] 
To KK-W, Tsang OT-Y, Leung W-S, et al. Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: An observational cohort study. Lancet Infect Dis  2020; 20(5): 565-74.
[http://dx.doi.org/10.1016/S1473-3099(20)30196-1] [PMID:  32213337] 
[57] 
Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res  2020; 30(3): 269-71.
[http://dx.doi.org/10.1038/s41422-020-0282-0] [PMID:  32020029] 
[58] 
Xu X, Han M, Li T, et al. Effective treatment of severe covid-19 patients with tocilizumabChinaXiv 
[59] 
Yang Y, Islam MS, Wang J, Li Y, Chen X. Traditional Chinese medicine in the treatment of patients infected with 2019-new coronavirus (sars-cov-2): A review and perspective. Int J Biol Sci  2020; 16(10): 1708-17.
[http://dx.doi.org/10.7150/ijbs.45538] [PMID:  32226288] 
[60] 
Yao X, Ye F, Zhang M, et al. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin Infect Dis  2020; 71(15): 732-9.
[http://dx.doi.org/10.1093/cid/ciaa237] [PMID:  32150618] 
[61] 
Zhang H, Penninger JM, Li Y, Zhong N, Slutsky AS. Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target. Intensive Care Med  2020; 46(4): 586-90.
[http://dx.doi.org/10.1007/s00134-020-05985-9] [PMID:  32125455] 
[62] 
Zhang L, Pang R, Xue X, et al. Anti-SARS-CoV-2 virus antibody levels in convalescent plasma of six donors who have recovered from COVID-19. Aging (Albany NY)  2020; 12(8): 6536-42.
[http://dx.doi.org/10.18632/aging.103102] [PMID:  32320384] 
[63] 
Zhou D, Dai S-M, Tong Q. COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression. J Antimicrob Chemother  2020; 75(7): 1667-70.
[http://dx.doi.org/10.1093/jac/dkaa114] [PMID:  32196083] 
[64] 
Zhong H, Wang Y, Zhang Z-L, et al. Efficacy and safety of current therapeutic options for COVID-19 - lessons to be learnt from SARS and MERS epidemic: A systematic review and meta-analysis. Pharmacol Res  2020; 157 ,104872
[http://dx.doi.org/10.1016/j.phrs.2020.104872] [PMID:  32360583] 
[65] 
Kumar Y, Singh H, Patel CN. In silico prediction of potential inhibitors for the main protease of SARS-CoV-2 using molecular docking and dynamics simulation based drug-repurposing. J Infect Public Health  2020; 13(9): 1210-23.
[http://dx.doi.org/10.1016/j.jiph.2020.06.016] [PMID:  32561274] 
[66] 
Elfiky AA. Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): A molecular docking study. Life Sci  2020; 253 ,117592
[http://dx.doi.org/10.1016/j.lfs.2020.117592] [PMID:  32222463] 
[67] 
Peele KA, Potla Durthi C, Srihansa T, et al. Molecular docking and dynamic simulations for antiviral compounds against SARS-CoV-2: A computational study. Inform Med Unlocked  2020; 19 ,100345
[http://dx.doi.org/10.1016/j.imu.2020.100345] [PMID:  32395606] 
[68] 
Shahab S, Sheikhi M, Alnajjar R, Saud SA, Khancheuski M, Strogova A. DFT investigation of atazanavir as potential inhibitor for 2019-nCoV coronavirus M protease. J Mol Struct  2021; 1228 ,129461
[http://dx.doi.org/10.1016/j.molstruc.2020.129461] [PMID:  33100379] 
[69] 
Shahab S, Sheikhi M. Triazavirin - Potential inhibitor for 2019-nCoV Coronavirus M protease: A DFT study. Curr Mol Med  2021; 21(8): 645-54.
[http://dx.doi.org/10.2174/1566524020666200521075848] [PMID:  32436829] 
[70] 
Sheahan TP, Sims AC, Graham RL, et al. Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. Sci Transl Med  2017; 9(396) ,eaal3653
[http://dx.doi.org/10.1126/scitranslmed.aal3653] [PMID:  28659436] 
[71] 
 SeyedAlinaghi S, Ghadimi M, Hajiabdolbaghi M, et al. Prevalence of COVID-19-like symptoms among people living with HIV, and using antiretroviral therapy for prevention and treatment. Curr HIV Res  2020; 18(5): 373-80.
[http://dx.doi.org/10.2174/1570162X18666200712175535] [PMID:  32652912] 
[72] 
Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med  2020; 382(18): 1708-20.
[http://dx.doi.org/10.1056/NEJMoa2002032] [PMID:  32109013] 
[73] 
Luo Y, Wang C-Z, Hesse-Fong J, Lin J-G, Yuan C-S. Application of Chinese medicine in acute and critical medical conditions. Am J Chin Med  2019; 47(6): 1223-35.
[http://dx.doi.org/10.1142/S0192415X19500629] [PMID:  31505937] 
[74] 
Ghiasvand F, Ghadimi M, Sadr S, et al. COVID-19 treatment success after repeat courses of azithromycin: a report of three cases. Infect Disord Drug Targets  2021; 21(6) ,e170721188439
[http://dx.doi.org/10.2174/1871526520999201126203510] [PMID:  33243134] 
[75] 
Jamali MSS, Zarezade B, Koolaji S, et al. Safety and effectiveness of high-dose vitamin C in patients with COVID-19: a randomized open-label clinical trial. Eur J Med Res  2021; 26(1): 20.
[http://dx.doi.org/10.1186/s40001-021-00490-1] [PMID:  33573699] 
[76] 
Sekhavati E, Jafari F. SeyedAlinaghi S, et al Safety and effectiveness of azithromycin in patients with COVID-19: An open-label randomised trial. Int J Antimicrob Agents  2020; 56(4) ,106143
[http://dx.doi.org/10.1016/j.ijantimicag.2020.106143] [PMID:  32853672] 

Rights & Permissions Print Cite

Article Metrics

88

1

Journal Information

For Authors

For Editors

For Reviewers

Explore Articles

Open Access

Open Access Articles

For Visitors

DOI https://dx.doi.org/10.2174/1871526521666210726150435	Print ISSN 1871-5265
Publisher Name Bentham Science Publisher	Online ISSN 2212-3989

Infectious Disorders - Drug Targets

Current Treatments and Therapeutic Options for COVID-19 Patients: A Systematic Review

Abstract

Graphical Abstract

Related Journals

Related Books

Related Articles